Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
as soon as is submitted to ZB.
KRAS degradation averts PDAC chemoresistance.
Nat. Cancer 5, 375-377 (2024)
Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Other
ISSN (print) / ISBN
2662-1347
e-ISSN
2662-1347
Journal
Nature Cancer
Quellenangaben
Volume: 5,
Issue: 3,
Pages: 375-377
Publisher
Springer
Publishing Place
Heidelberger Platz 3, Berlin, 14197, Germany
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute for Diabetes und Organoid Technology (IDOT)